Company Overview of Cellular Dynamics International, Inc.
Cellular Dynamics International, Inc. develops and manufactures human cells in the United States, Europe, Japan, and internationally. The company’s proprietary products include human cells in multiple cell types (iCell products), human induced pluripotent stem cells (iPSCs), and custom iPSCs and iCell products (MyCell products). It offers iCell Cardiomyocytes, which are purified human heart cells that beat in a dish and behave just like the heart cells found in the human body for in vitro drug discovery, toxicity testing, and chemical safety, as well as in vivo cellular therapeutics research and development, and stem cell banking; and iCell Neurons that are purified human neurons typical of ...
525 Science Drive
Madison, WI 53711
Founded in 2004
Key Executives for Cellular Dynamics International, Inc.
Chairman and Chief Executive Officer
President and Chief Operating Officer
Founder and Vice Chairman
Co-Founder, Chief Scientific Officer, Director and Member of Scientific Advisory Board
Compensation as of Fiscal Year 2016.
Cellular Dynamics International, Inc. Key Developments
Cellular Dynamics International, Inc. Presents at The Cell & Gene Meeting on the Mesa, Oct-06-2016 09:30 AM
Oct 4 16
Cellular Dynamics International, Inc. Presents at The Cell & Gene Meeting on the Mesa, Oct-06-2016 09:30 AM. Venue: La Jolla, CA 92037, United States. Speakers: Emile F. Nuwaysir, President and Chief Operating Officer.
Cellular Dynamics International Launches Opsis Therapeutics to Develop Cell Therapies for Treatment of Retinal Diseases
Sep 28 16
Cellular Dynamics International, Inc. announced a new venture, named Opsis Therapeutics. Formed on July 31, Opsis Therapeutics is focused on discovering and developing novel medicines to treat patients suffering from retinal diseases. The Opsis Therapeutics team brings deep expertise and a track record of developing breakthrough technologies and building next-generation cell therapeutic programs. Opsis Therapeutics is at the forefront of scientific research on retinal cell manufacturing and its application in the treatment of retinal diseases. The company will bring together a cross-disciplinary team of internationally recognized advisors and development partners with combined expertise in iPSC manufacture, iPSC differentiation into retinal lineages, retinal cell biology, preclinical modeling of retinal disease, and sub-retinal surgery. The company is pioneering new approaches to treating retinal diseases and their associated vision loss, and developing a pipeline of therapeutic candidates.
Cellular Dynamics International, Inc. Announces Launch of iCell Hepatoblasts to Enable Research
Sep 22 16
Cellular Dynamics International, Inc. announced the launch of iCell Hepatoblasts, liver progenitor cells generated from human induced pluripotent stem cells. These cells show promise for liver regeneration therapy research by enabling researchers to identify molecules capable of stimulating liver progenitor cell proliferation and growth. They also provide an in vitro cellular system for studying hepatic development and regeneration and they can be engineered to develop complex liver models for use in vitro and in vivo applications. Hepatoblasts are bipotential liver progenitor cells that can differentiate into either hepatocytes, cells that comprises the majority of liver tissue, or cholangiocytes, epithelial cells of the bile duct. CDI has cryopreserved iCell Hepatoblasts at the time point in differentiation between definitive endoderm and hepatocyte specification. iCell Hepatoblasts can be induced to differentiate into either hepatocytes or cholangiocytes, as dictated by the media conditions in which the cells are cultured. iCell Hepatoblasts retain proliferative capacity upon thaw. iCell Hepatoblasts can be co-cultured with other CDI cell types (such as iCell Endothelial Cells, iCell Hepatocytes and iCell Macrophages) to enable complex liver tissue regeneration and disease modeling.
Similar Private Companies By Industry
Recent Private Companies Transactions